» Articles » PMID: 19082742

P-gp Inhibition Potential in Cell-based Models: Which "calculation" Method is the Most Accurate?

Overview
Journal AAPS J
Specialty Pharmacology
Date 2008 Dec 17
PMID 19082742
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The objective was to directly compare the four different "calculation" methods of assessing P-gp inhibition potential using experimental data obtained from approximately 60 structurally diverse internal research and marketed compounds. Bidirectional studies for digoxin (probe for P-gp substrate) were performed with and without test compounds (at 10 microM). Four different calculation methods were applied to the same dataset (raw bidirectional permeability values) to obtain the "percent inhibition of P-gp" for these compounds using the different methods. Significantly different inhibition potential was obtained with the "exact" same experimental dataset depending on the calculation method used. Subsequently, entirely different conclusions regarding the "inhibition potential" of test compound was reached due to the different calculation methods. Based on the direct comparison of these methods, method no. 3 (i.e., inhibition of B to A permeability of digoxin) is recommended as the calculation method ideal during screening stages due to its high throughput amenability. The methodology is capable of rapidly screening compounds with adequate reliability for early stage drug discovery. Method no. 3 provides an abridged version of a bidirectional study that is fully capable of identifying all non-inhibitors (0-20%), moderate inhibitors (20-60%), and potent inhibitors (>60%) and demonstrates high correlation with method no. 1 (inhibition based on both A to B and B to A permeability of digoxin). Nevertheless, method no. 1 might be appropriate for more detailed mechanistic studies required in late stage discovery and development.

Citing Articles

Knockout Transporter Cell Lines to Assess Substrate Potential Towards Efflux Transporters.

Volpe D AAPS J. 2024; 26(4):79.

PMID: 38981917 DOI: 10.1208/s12248-024-00950-6.


In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models.

Chu X, Chan G, Houle R, Lin M, Yabut J, Fandozzi C AAPS J. 2022; 24(3):45.

PMID: 35314909 DOI: 10.1208/s12248-021-00677-8.


In Vitro Evaluation of P-gp-Mediated Drug-Drug Interactions Using the RPTEC/TERT1 Human Renal Cell Model.

Saib S, Hodin S, Bin V, Ollier E, Delavenne X Eur J Drug Metab Pharmacokinet. 2021; 47(2):223-233.

PMID: 34935100 DOI: 10.1007/s13318-021-00744-7.


Case Study 7: Transporters Case Studies-In Vitro Solutions for Translatable Outcomes.

Bhoopathy S, Bode C, Naageshwaran V, Weiskircher-Hildebrandt E, Mukkavilli V, Hidalgo I Methods Mol Biol. 2021; 2342:709-735.

PMID: 34272714 DOI: 10.1007/978-1-0716-1554-6_26.


Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans.

Min J, Kim D, Park J, Heo H, Bae S, Seo J Drug Des Devel Ther. 2016; 10:2959-2972.

PMID: 27695293 PMC: 5028085. DOI: 10.2147/DDDT.S109141.


References
1.
Watanabe T, Miyauchi S, Sawada Y, Iga T, Hanano M, Inaba M . Kinetic analysis of hepatobiliary transport of vincristine in perfused rat liver. Possible roles of P-glycoprotein in biliary excretion of vincristine. J Hepatol. 1992; 16(1-2):77-88. DOI: 10.1016/s0168-8278(05)80098-4. View

2.
Stephens R, ONeill C, Warhurst A, Carlson G, Rowland M, Warhurst G . Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther. 2001; 296(2):584-91. View

3.
Rautio J, Humphreys J, Webster L, Balakrishnan A, Keogh J, Kunta J . In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos. 2006; 34(5):786-92. DOI: 10.1124/dmd.105.008615. View

4.
Polli J, Wring S, Humphreys J, Huang L, Morgan J, Webster L . Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001; 299(2):620-8. View

5.
Troutman M, Thakker D . Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003; 20(8):1200-9. DOI: 10.1023/a:1025049014674. View